Skip to main content
Premium Trial:

Request an Annual Quote

Genosity, Igentify Collaborate on Genetic Counseling Software, Ink Comarketing Deal

NEW YORK – Genosity and Igentify announced Tuesday a strategic collaboration to integrate Genosity's Integrated Genomic Toolkit into Igentify's genetic counseling software.

Under the terms of the agreement, both firms will comarket the combined solution. Financial and other terms of the deal were not disclosed.

"Our integrated system not only provides a solution for the operational aspects of all genetic testing, from patient enrollment to result report, but also enables our clients to build their data-driven knowledge base that can help them advance research, improve patient care, and engage in commercial collaborations," Genosity CEO and Cofounder Marc Grodman said in a statement. The system will be able to interface with electronic medical records systems, the firms noted.

Israel-based Igentify is the latest partnership for genomics software and lab services provider Iselin, New Jersey-based Genosity, which also has comarketing agreements with ArcherDx and Personal Genome Diagnostics, a strategic collaboration with Olink Proteomics, and a research partnership with Columbia University to study wild-type cardiac amyloidosis, a rare heart disorder.

"Igentify is proud to combine our efforts with Genosity to allow the first of its kind comprehensive software solution that enables healthcare providers to establish genomic core centers of excellence comprising patient counselling, bioinformatics and a laboratory information management system for better patient care," Igentify CEO and Cofounder Doron Behar said in a statement. "Demand for genetic testing is rising quickly, but a shortage of genetic counselors makes it impossible to scale up personal genetic counselling services, leaving health care providers unable to fulfill patient needs."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.